Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ,III of locally advanced HER‐2 negative adenocarcinoma at gastroesophageal junction.
Epistemonikos ID: 3a422e92650660d4dd1453db4192ebf9f8edab56
First added on: May 22, 2024